ýêñòðàêò êîðåíü ëîïóõ ñóõ.

ÐÏࡱá>þÿ 6L")¦":;";":;";"K:;"àõÿ@ @ À àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ àõÿ ôÀ à@ @ À à,õÿ øÀ à*õÿ øÀ àõÿ À àõÿ À àõÿ @ @À à õÿ øÀ à+õÿ øÀ à)õÿ øÀ à @ @ À à @ À à 8@ À à*8@ @À à 8@ @À à! @@ À à! @ À à!  @ À à1 @@ À à1 @ À à1  @ À “€ÿ“€ÿ“€ÿ“'@09A-;8AB 3@C??0“-@09A-;8AB ?>43@C??0“%@09A-;8AB H0?:0“€ÿ“€ÿ“€ÿ`… @09A-;8ABŒ®  ;ÿ  ;KÁÁ€8ü „£ ! " 0.25 ". ! 60 !!   /% 2% 2 !10 !!"  /%  0.02 !' !10#  /%  0.04 !10 !! ! 10 " ! 6 "C? 1400'>@8A>2A:89 7-4 2, 5;0@CAL &" " 0.2 !10 &" " 0.5 !10 &" !  2,4% 50 &" !  2.4%-100.0"#! ! 10 "." ! 12 ""$#& 5  #+  !10"$#& 5  #+  !5#"!$ 0.1 ". !60 !!! !,   3% 100  !  !,   3% 40  ! "#!! 100  "#!! 100 /" -""/ & !" #' - 100 $ !, !-5B5@1C@3" !" !30$#& 2%-30,0  Yamanouchi, 845@;0=4K ! 10 Slovakofarma, !;>20:8O !" 100 D;0:>= 20 D;0:>= 72.$ ,  # !" 50  . 500 " !10 " 250 " !3  $!!, / " 750 !#! 15OXFORD LABORATORIES, / &" 0.2 " !60AD0@-!C465=A:"N<5=A:89 %$, "N@. 140% ! /%  5% 1 !10 !:>@. 260! " 75 !14 5  !5. 200. 400  100+ - 25 $ D;0:>= 54!"  " 0.75 !2 " !#+ !30   0.005 " !60 !!$  0.005 ". ! 100 !!C? 72  30 -1  !3 HB. 180* / , 0.5%-10.0 "#. !! #" 20 " !60 !" # 4 " !14 !" # 4 " !30 !"  2.5% 1 !10:>@. 1 "! , 10   /!#/ 100 " !10 PROTECH BIOSYSTEM PVT.LTD, / !"  100 . "$  100/ 10 !* &  /& "/ 0.5 " / !10 !! -! 250 ! !2 " 0.15 " !100WAVE PHARMACEUTICAL,/ " 0.15 " !20C? 340 " 0.30 " !10 " " !60 #" 0.002 " !10 $  3  ! 5 " -, ! !#  / / 5 -  / !5 " 0.5   ! 100 # " !21 # " !21 !3"  ",+ " !12 //"+/Hoffman la Roche, $@0=F8O#  ",+ ".! 24 /"/)  ",+ ".! 24 //"+ /!%/ . 200 . 400  " &"" 33000 ! !10 ! 0.2 ! 50 " "! , !"-" # C? 126 ! 2% 10 !10 ! 2% 5.0 ! 10  " /!"/ 1 " !10A $ , (& // !" " , !"--#  " /!"/ 1 " !20  " !10  & 3  " !10 !!Rhone-Poulenc Rorer, $@0=F8O  " 50  8;0@,>A:20 # 0.1  " !15 #"& 500 " !20!&-&/ !" 25.0 D;0:>= 70"!& -"+ ! " -  2%-40.0!,#" 12 - . !!!  0.1%-10 D;0:>= 240 0;5=0, '5E8O!  0.1% 10 ! !  -  0.05% 10!  "" !10 ROCHE,$ &/!- /!/ " !10MILVE,  /!- /!/ " !20!- " ! 10! " ! 500Cipla Ltd., =48O!"" !" ! 30C? 159! / ,  !"/ 40.0C? 99!$  " !30!,  - , 1% 50.0!,    1% 50.0!"& " 10% -25.0!"& " 5% -25.0C? 84!-!"  -  2%-1  !10:>@. 100! # 2 " !30NOVARTIS PHARMA,  /! # 4 " !30!" 3.0 ! 30Beaufour-Ipsen, $@0=F8O!" 3.0 !10! " !" . !12%! $  # #! 320/60 !30 " !&! $  # #! 320/60 !50 " !!! 5.0 . . !5! " !20! ". !100!  5.0 !10! " !20!&!" 10 $*! " / ("/ 25 " !20C? 1251>;5=A:>5 $, >A:>2A:0O >1;&!""#!! 100 $" !  !  $!""#!! 4/100 " !20!" !! /" + !16Boots Healthcar, 5;8:>1@8B0=8O!" !! ! " ! !24 !" "& !#,$" 1.0 !!!#,$"! 0.5 !10 !#,$&-" /  20%-1,3 !2>A:>2A:89 M=4>:@.7-4, >A:20%!#,$&-" /  20% 1 !2 !!5;<54?@5?0@0BK, 5;0@CAL!#,$&-" / -  20%-10 < %!#,$&-" / -  20%-5  !!80D0@@20B8O" ! , 2% 40,0" ! #" 2% , 40.0" ! #"   ! !50"  !! " / 100 !30'LANNACHER HEILMITTEL GES.M.B.H ,!" /"  !! " / 50 !30!#, " + 0.25 " !10#"   ! 50C? 192 #!  500 " ( !16 !!#!  ".! " ( !10 !# ! 25.0 . $.0;8GD0@;LH0$#&  0.025% 15.0 ,$. !  #+  !5 $"$  , "'$/ !" 0.001 " !5010=:0 60 $ !  -  2850/0-3 !10$  250 " !14$" 0.5 !10$#  0.05 " !30$#  0.05 !10$# ! 1%  2 !10 !$# ! 40 " !50 !% $ " 100 % $ "  30!% $" 2% 20 !. -  $+"+ - &!, #  % $" -  ! ". 1% 100%  10.0% !50 " /%!! !  300,0 $.% "-! 5% 30 ,%## NPH 3!5 !!ELI LILLY, $ &/&   1 !10Ebewe, 2AB@8O& # 10 " !50& #/& #/ / 2 !10"&$ " .!, 1.0 / /$&$ " .!, 1.0 /$&$  0.1 !' !10&$  0.25 !' !10&$"! 1,0 /&$   12.5% 2 !5!, !-" # &/ , 25.0&  0.025 !10 "&  0.025 !50 &  0.025 !50 "1=>2;5=85 $, >2>A818@A:& " 250 " !10 !!& " 500 " !10 !!& $!&-  0.25 !10& $!& 0.25 !10 !& $!& 0.5 !10 !C? 92&"  -  " ! 10&"  -  " ! 6' "" 0.075 " !28ORGANON,  +($ !" / !!!. !12($ " / !!!. !20($ " / !!!. !24-" " / !!. !12-" " / !!. !20- 50 !60 !!-" 2.5 " !28-!   # 25-! 1% 5 + -  / / 10 " !20C? 171-  / / 5 " !20!-  10 " !20  !-  20 !20 >2>2>A818@A:%-  20 " !20 HEMOFARM !Hemofarm, .3>A;028O!-  20 " !20  !#-  20 " !20 !"! !!"!, !!/ -  5 " !20  !"-  5 " !20 !"! !- 10 " !20- 2@. 25-$$  0.5 " ( !16-$$  " ! !10-$$  " . -  90-%& !" 50 $  !"+ " +   ) 100C? 54!, !-" # "/  , 50 ,, ! $" !   50.0/ 10.0  ( + !",/ . 30.0 # -$ , !!/ !",!! " &" 35.0/ +( + 50 #! !",/ . 50.0  +  , $/ !20#   . 50.0  -!-" ,  # / "  1.5 $/ ! 20$ -$  , !"-" #  / "  50.0   + / 50.0 + !",/ 50.0 !+  , 25 #(+   50.0(## #+ !" ! +,& . 30.0 (## #+ !" ! +,& . 50.0 !!+ "  $/ 1.5 !20, + 50.0 !/ #!" . 50.0  /"+  ' !",/ . 50.0 !/"+  ' !",/ $/ !20 1.5#'   100.0#'   50.0  "!$ "+' !",/ 25.0  "!$ "+' !",/ 50.0# "!$ "+' !",/ $/ !20!!"#(, !# "  . 50.0 ,!"#(, !# "  . 50.0  //"/ #/   ,( !",/ 50.0+  , "  50#!"+  "  . 50.0  !" ( ! 100.0!!$" 0.8%0.7 "+.)/ !!/.!   + 8.0 $ !   /-!"  +/(, ! , !!!, /   1000 /"/!"%!, ! !!!, /   500.0 /"/%!$,/ 125.0   / /-!"  //'!$,/ 75.0   / /-!" " //%!$,/ 75.0   /" /'+ //+!$,/ , !!+ 75 / !#'  /0!$,/ ,  .) 75 /'+ !/!!", 75   /ALFA INTEL, ,(6! , #" "' ANCORA DE COBRE 375 NORMAL /,/EUROGINE SL, !/6! , #" "' T DE ORO 375 NORMAL /,-"/9! , #" "' T DE PLATA 380 NORMAL /,-!  //! !" / " /  90% 253 " #.) $$"$ , !"-" #  ! !" / 5  2  !10)! !" / /"/   !"-1 250.0! , '/!"+  !20 .!$ ,  !/ !","+  !20 "+  SUPER PLUS / !8"!"   !",,W.H.P.M. BIORESEARCH TECHNOLOGY CO. LTD. CPR"!"   !",  /!(/Miltom Inc, !(' , /  75(#, % , 420  /# (#, % , 420 #%/%,(#, % ,   420(#, % , +, 420(#, % , '  420(#, % , ( 420( "+ / %#/ L( "+ / %#/ M( "+ / %#/ S&! ,%+?0@0 5" ,/ #( ! !"  !2" ,/ #( ! !"  !3'" ,/ #( ! !"  / &+'" ,/ %  / !"  !"  !4!".   ! 58 158-164HB.!;028O, >2>A818@A:!".   ! 58 164-170!".  # 8  58 ,,  ! $!". . .  ! 58  164-168 !". . .  ! 58  170$!". . . # ! 46  170-176$!". . . # ! 50  170-176$!". . . # ! 50  170-178$!". . . # ! 52  170-176$!". . . # ! 56  170-176$!". . . # ! 58  170-176$!". . . # ! 60  170-176!  ULMA TECHNICAL PRODUCTS LTD$ "#  0&+ +$ "#  +$ "# /-" +%" . % # '!" $ , ! %" % # (- /14-42/ /!(- $! /14-25/ #/!(- $! /18-35/ #/WEIHAI MEDICAL POLYMER, "(- $! /18-42/('- " ( "(' - "   "!"/)  & ! !! HB. 12"! , "< %  / / /'  '/"! , ",-  150.0!  .  135.0 /SEMPER, (&/)' /"HB. 48 '" '" DERMA CLEAN . 7-8Ansell GmbH, 5@<0=8O) '" DERMAGRIP HIGHRISK POWDER FREE L?0@0 25WRP ASIA PACIFIC, /* '" DERMAGRIP HIGHRISK POWDER FREE XL) '" DERMAGRIP HIGHRISK POWDER FREE  '" NITRO TEX .6-7?0@0 50# '" "'! !8 /  /?0@0 15*@2KE 8745;89, @=578O$ '" /!"  !"  PERRY X-AM .LAnsell Perry, !($ '" /!"  !"  PERRY X-AM .M6 '" /!"  !"  SYNSATION POWDER + P.6/7Ansell GmbH, 0;0978O6 '" /!"  !"  SYNSATION POWDER + P.8/9) '" /!"  !"  " #  .L /SFM/SFM Hospital, 0;0978O) '" /!"  !"  " #  .M /SFM/) '" /!"  !"  " #  .S /SFM/# '" /!"  !"  " .L DYNAX3INTERNATIONAL MEDICAL PRODYUCTS, !(-/-"' '" /!"  !"  " .M IMP # ' '" /!"  !"  " .S IMP # 5 '" /!"  !"  "  DERMAGRIP NITR #  M1 '" /!"  !"  "  SEMPERCARE "!"#  LSEMPERIT, "+ '" /!"  !"  "!"#  DERMAGRIP P.L+ '" /!"  !"  "!"#  DERMAGRIP P.M+ '" /!"  !"  "!"#  DERMAGRIP P.S9 '" /!"  !"  "!"# . #  .L /SFM/ !""9 '" /!"  !"  "!"# . #  .M /SFM/ !""9 '" /!"  !"  "!"# . #  .S /SFM/ !""  '" /!"  %  !7 /  /  '" /!"  %  !8 /  /5 '" /!"  % #  " ULTRA ONE PLUS P.S "!"# + '" /!"  % #  " .6 SFM HOSPITAL- '" /!"  % #  " .6.5 SFM HOSPITAL?0@0 500- '" /!"  % #  " .7.5 SFM HOSPITAL" '" /!"  % #  " .L IMP$ '" /!"  % #  " .M DYNAX;INTERNATIONAL MEDICAL PRODYUCTS, !(-/-"-"" '" /!"  % #  " .M IMP" '" /!"  % #  " .S IMP '" -" L '" -" ' '" !"  #( ! DONA 410 .7?0@0 45Vulcan a.s., '5E8O' '" !"  #( ! DONA 410 .8) '" !"  #( ! DONA 410 .8.51 '" !"  % #  " .6 SFM HOSPITAL !1 '" !"  % #  " .8 SFM HOSPITAL ! '" !"  % #  . 6 SFM '" !"  % #  . 6.5 SFMSFM Hospital Products, 5@<0=8O '" !"  % #  . 7 SFM '" !"  % #  . 7.5 SFM '" !"  % #  . 8 SFM '" !"  % #  . 8.5 SFM '" !"  % #  .6 DYNAX&INTERNATIONAL MEDICAL PRODYUCTS, " '" !"  % #  .6.5 IMP '" !"  % #  .8 IMP '" !"  % #  .8.5 IMP$ '" % #  !"  MEDI GRIP .6.5" '" % #  !"  MEDI GRIP .7$ '" % #  !"  MEDI GRIP .7.5" '" % #  !"  MEDI GRIP .8 + /    !18523C<0, #:@08=0    !2#, #     !3  +'/ !1+  !!/ % / # 100/ 3>=. 100%82>A818@A:% / / # 45/ 3>=. 45#- ' / # -! %  .*-  #/  !" #", ".,' +   " CONTEX !3 BLACK ROSE(AVK POLYPHARM INVESTVENT,  "/*  " CONTEX !3 #! !  " )  " CONTEX !3 #! !  !"+)  " CONTEX !3 #! ! ! &*  " CONTEX !3 #! ! !& $ +-  " CONTEX !3 #! ! "'   +  " CONTEX !3 #! ! #  &  " CONTEX !3 #! ! ' ++  " VIZIT !3 HI-TECH ,(  #CONDOMI ERFURT PRODUCTIONS, /(  " VIZIT !3 HI-TECH ! %"#  " VIZIT !3 ! $! ,&)  . 4&  #"+ / .. ' .#+ , /, !1#+ , /, !3#!"+( (HB. 250#!"+( ( !2#!"+( ! ,HB. 220#!"+( /!! '/HB. 350" # " 2   5%1.5:3 5;LD0?;0AB8:, >A:20( &+  +    "  ,& 0.30*13 SFM  < /  ,& 0.40*13 SFM  /  ,& 0.45*16 SFM  /  ,& 0.60*25 SFM  /  ,& 0.70*30 SFM  /  ,& 0.80*40 SFM  /  ,& 0.90*40 SFM  / ,& 1.2*40 SFM  /( & 1  /3-%/ B-D !BECTON DICKINSON, !(( & 1  /3-%/ SFM( & 10  /3-%/ SFM( & 10  B-BRAUNB. Braun, 5@<0=8O( & 10  BECTONBecton Dickinson, A?0=8O( & 10  CHIRANACHIRANA T. INJECTA, !/( & 10  LEBSACKLebsack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gio Pharmaceuticals Ltd, =48O!!" !" !24 -"-"" !. !10., " #    ! , 30:@8E8= %$, >A:20" 80/2 !25 .Nycomed, 2AB@8O-,"&  ( " !10C? 20Bayer AG, < 5@<A:E8<D0@D0@AE8<D0@A:20,  170 !#!. $. D;0:>= 30Balkanfarma, >;30@8O,  170 !#!. $.- -!" " 1.0 . . ! 10    $, !" ,$#" 10/ 1  !10C? 60"%!, #+/!,# 10% 100  -  $. !D;0:>= 19@54?@8OB85 ?> ?@>872>4AB2C 10:. ?@5?0@0B>2, :0B5@8=1C@3$,& 50 / - , 200Schering-Plough, 5;L38O,!  - , 10% 90.0ALDO-UNION, !/ 1.0 "/( & !3:>@. 50Merckle GmbH, 5@<0=8O'  0.015/5.0 . !  100.0 .C? 50  0.030 ". !20 ! 30 " !20Hexal, 5@2A:89 28B02>  / -" 5%-100.0 C? 36  ". 0.2 !30 !!C? 160! / , !!" " 25 ". !50 !!@K=F0;>2, >A:20-=4>:@8==K9 7-4, 3. >A:20%! 156/5   /!#! 100.0 Lek, !;>25=8O! 375 " !15&& " . !, 0.5  . !!!8=B57, C@30=%& "  " 0.25 !10 !!C? 108(& "  " 0.25 " !20 !,-% ". !20Sopharma, >;30@8O, 50% 1  . !10C? 1209 !8 -= :BO1@L, !-5B5@1C@3, 50% 2  . !109 !8 -= >;8D0@@1, 5@<LC? 174$  "! " !20 ". !10C? 500$0@=, !-5B5@1C@3!" !' !1086D0@23>@>4"- " / !!! !20NATUR PRODUCT, $ &/" - ! !20=B828@0;, !0=:B-5B5@1C@3"  ( " !10C? 64"  ( " !30 /"C? 18#"!"'. -  &. 70% 100 $ D;0:>= 40!""-$  - !!/#"!"'. -  &. 95% 100 $$ ! ", !" %,  0.1 ". !100;LE8<D0@2A: $ "  " / 1.5 !30Servier, $@0=F8O $ " / 2.5 !30 " 0.002 " !30# #" 0.25% 5.0    !!Chavvin Ankerpharm, 5@D0@@>4! / -" 2.5  .C? 600! / -" 5% 2 !10 02>A81E8<D0@2>A818@A:! #" " !10$"%, !@30=8:0, >2>:C7=5F:! #" " !508>A8=B57, 5=70!  0.5 ". !10 !!HB. 400!  0.5 ". !50HB. 500%$ , #!HB. 608>E8<8:, !0@0=A:.HB. 228HB. 36"0BE8<D0@<?@5?0@0BK, 070=LHB. 66!  " !50 !!" !" !".(/-" !16C? 162!Fermentapharma Biotech Ltd, =48O!"-  100 " !30 !C? 80 "-  50 " !30 !" 50 " !30C? 156NATUR PRODUKT,  +"" " -  20/ 200  !"Boehringer Ingelheim Gmbh,5@= 28&!, 400  $ ! D;0:>= 15!& -!   5% 2 ! &&- 600 ". (. !10 !&& 100  #/" !20 !!&& 100 ( " !20 !!&& 200  #/" !20 !!&& 200 ( " !20$&&   /   /'. 0.6 !6 !C? 140#-& "  !, 1  !@0AD0@O@A:, "/  4.0HB. 10Danaph, L5B=0<   5.0   !5Aventis, =48O   " !100C? 94AVENTIS, / /!"!, !!/  ". ! 6, " !20 #  10 200 - ! "  100 10 -  !!C? 168#" 0.2 !#. . !14 !!C? 70 EGIS,  /" 20.0 ,C? 40"!  8 " !30SOLVAY PHARMA,  +"" 0.25% .  5Alcon, 5;L38O"" 0.5% .  5$# -  100 $C? 30%!-,"$  0.01 !# " !10 ,"$  , !!/ !", !-$  !' 10 !10! 0.05 ". !30$!"-!" 0.12 " !20 !C? 144$!"-!" 0.48 " !20 !C? 76!" 0.12 ;LH0!" 0.48 " !20 !! Polfa, >;LH0$ !#% 5  !10    $, #$&-3 1200000    $ D;0:>= 50&-5 1.5   . $  -"+ 10  ( $ D;0:>= 100$$0@= 64$ $ ,   ! 8  -%   !25C? 15Berlin-Chemie AG, 5@;30@8O %-# 7 !. !10 %" 125 !  $ D;0:>= 48 !"$ , !!/#" , 5% 20 , 25.0 C? 48$ $ ,  ! $$  $ &"'!/ , !" %, + !" 30.0 . $. D;0:>= 42 0.06 ! . " !10C? 4609 !8 -= 5:A@54AB20, C@A: 0.06 " !10 0.06 " !6C? 864;B0928B0= 110Krewel Meuselbach GmbH,5@= 60 $  2.5 " !100Nycomed Dak AS, 0=8O" # . ". !30" # ,& . ". !30 20  /   $C? 24BITTNER RICHARD, !" /" -  200 !!GLAXO SMITH KLINE, ,( ! 0.1 ". ! 6 (  " 25 !20 !!  ". !10 " !10C? 800%&"-  0.005 ". !50 !&" 0.005 ". !20C? 244-$ , !!&" 0.005 ". !50 !!C? 117"-#  . 10CIBA VISION,$ &/"" !! ". !30"(  ". !30" # ,." " !60 Unipharm, !( " #   " / !100 !" # " !100 /. 5.0 . . !10C? 35 0.05% 10  $ 0.1% 10  $!"  50 $ !1!" " !30 Pliva, >;LH0!" " !60C? 8!" $  ". !6Pharmachim, >;30@8O!" & 25 " !50 !!" & 50 " !50 !!!  " (/ 50.0 KREWEL MEUSELBACH GMBH,  /!"   !505@>D0@@>=56!  0.2% -  40PARKE-DAVIS, $ &/ 200.0  $ D;0:>= 24 400.0  $ D;0:>= 12"   !50$"& !#,$ 4% 2  !10 !!C? 55$"&/ , 0.1% 15.0 !!"!  $ 50 !. !30'  " 125/5 !#! !1 $!!  " , 0.5% 3.0 ! JELFA, ,(   " , 1% 10.0 !" " 100 !20 !!Chinoin, 5=3@8O!"# 1.0 !#% . !5HB. 70<?@5?0@0B, #D0! ". !100Glaxo India Limited, =48O &  25.0C? 42 &  40.0&  40.0 / / -""/& + !' 2.11 !10. 10%-200 $ !. 40%-10  !10 !C? 25 ''-" !10>28A-97, >A:20 !" ! ! !10STADA,  /- 0,12 " !56C? 105YAMANOUCHI,  +/ !!/" ". !10 #D028B0, #D0 ! 0.05 !2C? 300 ! 0.15 "!" 0.0005 ". !50#!" 4/1  !25 !!:>@. 120)KRKA, !//" -, ! !!!" 4/1  !5 !M. G. BIOPHARM PVT LTD, /$ %  0.3 ". /. !100Sanofi-Winthrop, $@0=F8O 0.05  . !10 0.1  . !10-35   !21SCHERING,  / 0.02 ". !10C? 1000 1% 5   !10C? 43-$ / 0.1% 5 $/PROMED EXPORTS LTD, /% 0.075-3.0 . . !5 !! 0.1 ". "  !20 1%-50.0 , ".."$-,"$  100 !# !10!$-,"$  50 !# !10 $-! 2.5% 3 !10 !$-$ " 50 ". !20C? 250AJAKA-80, / / !" " , !"--#$ 100 ". !20$ 25 ". !30C? 520$$ " / 2.5% 3 !5 !! $ "  0.1 !20 !!$SHREA LIFE SCIENCES PVT. LTD., /  0.05 ". !10C? 1500 !  "+, !"--#  1% 1   !10C? 104C? 2608>AB8@, #:@08=0 " 10 " !ðàçäåëû êîñòðîìà ðèåëòîð êóïèòü ïê renu multiplus 355ìë ìàøèíà r-600 êóïèòü îòâåä âðà÷-ãèíåêîëîã ïðàìûøëåíûé àëüïèíèçì õîëîäèëüíèê neff îõîòà áûêîâà áèëåò áàëåò óðîê îõîòà ñúåìíûé çóáíîé ïðîòåç ñãëàç li-da ìåäèöèíñêèé ïåðåâîä âðà÷ àêóøåð ãèíåêîëîã ñåëèí äèîí áèëåò ñíåãîóáîðî÷íûé ìàøèíà ïðàéñ çåðêàëî ìåæäóíàðîäíûé êîíêóðñ äåáþòàíò êîñòðîìà êîììåð÷åñêèé çåðêàëî babyliss neri karra êîæãàëàíòåðåÿ àâòîøêîëà ÷åðíûé êîôå àêðèëîâûé ïðÿæà êîìïàíèÿ äîìèíèêå ïîìûòü ïîòîëîê ôëþðèñöåíòíàÿ êðàñêà ýëåêòðîòåëüôåð àïãðåéä îáåçüÿíà êóïèòü õëåáîïå÷êó pki êîëîêåéøí íàáîð ãèíåêîëîãè÷åñêèé âûøèâêà ôëàã áåíçîïèëà dolmar êóïèòü ìèíèìîéêó òðîéíèê àðõûç ïîñòàâêà òðîéíèê ïåðåõ ýêñòðàêò êîðåíü ëîïóõ ñóõ.